Thrive rakes in $257M to advance multicancer liquid biopsy

By LabPulse.com staff writers

July 30, 2020 -- Cambridge, MA-based startup Thrive Earlier Detection has raised $257 million in a new round of financing, which the company plans to use to advance its CancerSeek multicancer liquid biopsy test into a "robust" trial supporting regulatory approval.

The Series B financing round was led by Casdin Capital and Section 32, as well as new investors Bain Capital, Brown Advisory, and other companies.

Thrive launched in May 2019, with $110 million in financing from Third Rock Ventures with Section 32, Casdin Capital, BlueCross/BlueShield Venture Partners, and other firms. The CancerSeek test was developed at Johns Hopkins University as a detection method for multiple tumor types, including those that are difficult to screen for, such as cancer of the ovaries and pancreas.

Thrive presented results for the test from a large study of women with no history of cancer and undergoing screening at the American Association for Cancer Research virtual meeting in April. The data suggest that the percentage of screen-detected cancers increased from 25% to 52%, the company reported at the time.

Insurance coverage of liquid biopsies for cancer surges
An increasing number of insurance policies are covering liquid biopsies for cancer, according to a study published in the July 2020 issue of the Journal...
AI-driven DNA methylation liquid biopsy shows promise in brain and kidney cancer
A new liquid biopsy method based on DNA methylation and powered by artificial intelligence (AI) demonstrated promising performance at classifying brain...
Thrive blood test, PET/CT a winning combination in multicancer screening
An investigational blood test paired with positron emission tomography/computed tomography (PET/CT) imaging showed potential for increasing the yield...
Grail mulls LDT option for multicancer liquid biopsy test
Grail is considering options for launching its multicancer blood test as a laboratory-developed test (LDT) through its CLIA lab, following a presentation...
Thrive lifts off with multicancer liquid biopsy test
Startup company Thrive Earlier Detection launched on May 30, with $110 million in series A financing to develop the CancerSEEK liquid biopsy test...

Copyright © 2020 LabPulse.com

Last Updated ls 7/30/2020 11:09:09 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email